Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Evoke Pharma, Inc. (EVOK) had Return on Tangible Equity of -34.39% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$4.28M |
|
$-1.16M |
|
$0.10M |
|
$4.18M |
|
$5.42M |
|
$-1.14M |
|
$-0.02M |
|
$-1.16M |
|
$-1.16M |
|
$-1.16M |
|
$-1.16M |
|
$-1.16M |
|
$-1.16M |
|
$-1.14M |
|
$-1.14M |
|
2.56M |
|
2.56M |
|
$-0.45 |
|
$-0.45 |
|
| Balance Sheet Financials | |
$15.54M |
|
-- |
|
$0.11M |
|
$15.65M |
|
$12.24M |
|
-- |
|
$0.05M |
|
$12.29M |
|
$3.36M |
|
$3.36M |
|
$3.36M |
|
1.72M |
|
| Cash Flow Statement Financials | |
$-2.08M |
|
-- |
|
$0.06M |
|
$13.60M |
|
$11.58M |
|
$-2.02M |
|
$0.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.27 |
|
-- |
|
-- |
|
-- |
|
1.49 |
|
97.62% |
|
-26.56% |
|
-26.56% |
|
-- |
|
-26.99% |
|
-26.99% |
|
$-2.08M |
|
-- |
|
-- |
|
-- |
|
0.27 |
|
0.17 |
|
1.34 |
|
67.03 |
|
-34.39% |
|
|
Return on Tangible Equity |
-34.39% |
-7.39% |
|
-34.39% |
|
$1.95 |
|
$-0.82 |
|
$-0.82 |
|